Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-21T12:10:49.331Z Has data issue: false hasContentIssue false
  • English
  • Français

TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM

Published online by Cambridge University Press:  09 January 2013

Aileen Murphy ,
Elisabeth Fenwick ,
William D. Toff ,
Matthew P. Neilson ,
Colin Berry ,
Neal Uren ,
Keith G. Oldroyd  and
Andrew H. Briggs
Aileen Murphy
Affiliation:
Department of Economics, University College Cork
Elisabeth Fenwick
Affiliation:
Health Economics & Health Technology Assessment, University of Glasgow
William D. Toff
Affiliation:
Department of Cardiovascular Services, University of Leicester
Matthew P. Neilson
Affiliation:
Health Economics & Health Technology Assessment, University of Glasgow
Colin Berry
Affiliation:
BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences
Neal Uren
Affiliation:
Royal Infirmary of Edinburgh, Edinburgh Heart Centre
Keith G. Oldroyd
Affiliation:
Golden Jubilee National, West of Scotland Regional Heart & Lung Centre
Andrew H. Briggs
Affiliation:
Health Economics & Health Technology Assessment, University of Glasgow
Get access Rights & Permissions [Opens in a new window]

Extract

Aortic stenosis (AS) is caused by age-related calcific degeneration of the aortic valve (1). Initially, cases are asymptomatic but, from the point that symptoms first develop, there is rapid progression and if left untreated survival estimates are low (2–3 years) (1). Therefore, managing AS effectively and efficiently is a priority for health systems with increasing healthcare costs and longer life expectancy.

Keywords

Cost-effectiveness analysisValue of information analysisEVPIEVPPITAVI
Type
ASSESSMENTS
Information
International Journal of Technology Assessment in Health Care , Volume 29 , Issue 1 , January 2013 , pp. 12 - 19
Copyright
Copyright © Cambridge University Press 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Vahanian, A, Alfierib, OR, Al-Attara, N, et al.Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2008;34:1–8.CrossRefGoogle Scholar
2.Leon, MB, Smith, CR, Mack, M, et al.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.CrossRefGoogle ScholarPubMed
3.Bonow, R, Carabello, B, Chatterjee, K, et al.2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118:e523–661.Google Scholar
4.Cribier, A, Eltchaninoff, H, Tron, C, et al.Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol. 2004;43:698–703.CrossRefGoogle ScholarPubMed
5.NICE. Transcatheter Aortic Valve Implantation for Aortic Stenosis. London: NICE; 2012.Google Scholar
6.SHTG. Advice Statement 005/11: Transcatheter Aortic Valve Implantation. London: Group SHT; 2011.Google Scholar
7.Scottish Parliament. Offical Report Debate Contributions: Meeting of the Parliament 29 March 2012, Health Wellbeing and Cities Strategy; Heart Surgery. Edinburg: Scottish Parliament; 2012.Google Scholar
8.Webb, JG, Pasupati, S, Humphries, K, et al.Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation. 2007;116:755–63.CrossRefGoogle ScholarPubMed
9.Descoutures, F, Himbert, D, Lepage, L, et al.Contemporary surgical or percutaneous management of severe aortic stenosis in the elderly. Eur Heart J. 2008:1410–7.CrossRefGoogle ScholarPubMed
10.Grube, E, Schuler, G, Buellesfeld, L, et al.Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second-and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol. 2007;50:69–76.CrossRefGoogle ScholarPubMed
11.Grube, E, Laborde, JC, Gerckens, U, et al.Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation. 2006;114:1616–24.CrossRefGoogle ScholarPubMed
12.Gilbert, T, Orr, W, Banning, AP. Surgery for aortic stenosis in severely symptomatic patients older than 80 years: experience in a single UK centre. Heart. 1999;82:138–42.CrossRefGoogle Scholar
13.Gehlot, A, Mullany, CJ, Ilstrup, D, et al.Aortic valve replacement in patients aged eighty years and older: early and long-term results. J Thorac Cardiovasc Surg. 1996;111:1026–36.CrossRefGoogle ScholarPubMed
14.Milano, A, Guglielmi, C, De Carlo, M, et al.Valve-related complications in elderly patients with biological and mechanical aortic valves. Ann Thorac Surg. 1998;66 (Suppl 1):S82–7.CrossRefGoogle ScholarPubMed
15.Eichinger, W, Hettich, I, Ruzicka, D, et al.Twenty-year experience with the St. Jude medical Biocor bioprosthesis in the aortic position. Ann Thorac Surg. 2008;86:1204–10.CrossRefGoogle ScholarPubMed
16.Aupart, M, Mirza, A, Meurisse, YA, et al.Perimount pericardial bioprosthesis for aortic calcified stenosis: 18-year experience with 1133 patients. J Heart Valve Dis. 2006;15:768–75.Google ScholarPubMed
17.Legrand, V, Beckers, J, Fastrez, M, et al.Long-term follow-up of elderly patients with severe aortic stenosis treated by balloon aortic valvuloplasty. Importance of haemodynamic parameters before and after dilatation. Eur Heart J. 1991;12:451.CrossRefGoogle ScholarPubMed
18.Yan, T, Cao, C, Martens-Nielsen, J, et al.Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: a systematic review. J Thorac Cardiovasc Surg. 2010;139:1519–28.CrossRefGoogle ScholarPubMed
19.Straumann, E, Kiowski, W, Langer, I, et al.Aortic valve replacement in elderly patients with aortic stenosis. BMJ. 1994;71:449–53.Google ScholarPubMed
20.Netten, A. Unit Costs of Health and Social Care. University of Kent at Canterbury. Personal Social Services Research Unit: Citeseer; 1996.Google Scholar
21.Ahmed, A, Aronow, W, Fleg, J. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J. 2006;151:444–50.CrossRefGoogle ScholarPubMed
22.Maliwa, M, van der Heijden, G, Bots, M, et al.Quality of life and NYHA class 30 years after mechanical aortic valve replacement. Cardiovasc Surg. 2003;11:381–7.CrossRefGoogle ScholarPubMed
23.Rao, C, Aziz, O, Panesar, SS, et al.Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ. 2007;334:621.CrossRefGoogle ScholarPubMed
24.Briggs, AH, Claxton, K, Sculpher, MJ. Decision Modelling for Health Economic Evaluation. Oxford: Oxford Oxford University Press; 2006. 237 p.CrossRefGoogle Scholar
25.Webb, J, Cribier, A. Percutaneous transarterial aortic valve implantation: what do we know? Eur Heart J. 2011;32:140.CrossRefGoogle ScholarPubMed
26.McCabe, C, Claxton, K, Culyer, A. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26:733–44.CrossRefGoogle ScholarPubMed
27.Bleiziffer, S, Mazzitelli, D, Opitz, A, et al.Beyond the short-term: clinical outcome and valve performance 2 years after transcatheter aortic valve implantation in 227 patients. J Thorac Cardiovasc Surg. 2012;143:310–7.CrossRefGoogle ScholarPubMed
28.Schaff, HV. Transcatheter aortic-valve implantation-at what price? N Engl J Med. 2011;364:2256–8.CrossRefGoogle ScholarPubMed
29.Reynolds, MR, Magnuson, EA, Wang, K, et al.Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosisclinical perspective results from the Placement of Aortic Transcatheter Valves (PARTNER) Trial (Cohort B). Circulation. 2012;125:1102–9.CrossRefGoogle Scholar
30.Moat, NE, Ludman, P, de Belder, MA, et al.Long-term outocmes after trancatheter aortic valve implantation in high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2011;58:2130–8.CrossRefGoogle Scholar
31.Kennon, S, Kapur, A, Rothman, M, et al. Percutaneous aortic valve replacement: Clinical and Economic Considerations. 2008. Unpublished Manuscript.Google Scholar
32.Kalra, L, Evans, A, Perez, I, et al.A randomised controlled comparison of alternative strategies in stroke care. Health Technol Assess. 2005;9:1–94.CrossRefGoogle ScholarPubMed
33.NHS. National Schedule of Reference Costs 2006–07 for PCTs. London: National Health Service; 2008.Google Scholar
Supplementary material: File

Murphy Supplementary Material

Appendix

Download Murphy Supplementary Material(File)
File 212.5 KB